menu
    • menu
    [{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK115","moa":"NGF","graph1":"Neurology","graph2":"Preclinical","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AC Immune","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Anti-TDP-43 antibody","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ AC Immune","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ AC Immune"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"BHV-8000","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0.96999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.96999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"DP Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DPT0416","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DP Technology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"DP Technology \/ Undisclosed"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RAG-21","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Partnership","leadProduct":"SPU-16","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"WuXi AppTec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi AppTec \/ Silo Pharma","highestDevelopmentStatusID":"4","companyTruncated":"WuXi AppTec \/ Silo Pharma"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"University Medical Center Utrecht","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ University Medical Center Utrecht","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ University Medical Center Utrecht"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ractigen Therapeutics

                            China arrow
                            Aquaexpo
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-21

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ractigen Gains FDA Orphan Designation for RAG-21 in ALS Therapy Development

                            Details : RAG-21, its novel siRNA therapy targeting the FUS gene by reducing its level, for the treatment of FUS-amyotrophic lateral sclerosis

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 19, 2024

                            Lead Product(s) : RAG-21

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            WuXi AppTec

                            China arrow
                            Aquaexpo
                            Not Confirmed

                            WuXi AppTec

                            China arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPU-16

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Silo Pharma Announces Partnership with Global CRO for CNS Homing Peptide

                            Details : Through the partnership, Silo Pharma will advance the development of the SPU-16 for an early-stage study, a central nervous system homing peptide targeting multiple sclerosis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            August 07, 2024

                            Lead Product(s) : SPU-16

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DP Technology

                            China arrow
                            Aquaexpo
                            Not Confirmed

                            DP Technology

                            China arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPT0416

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DP Technology Nominates CNS-Penetrable LP-PLA2 Inhibitor For Alzheimer's Disease

                            Details : DPT0416 is a novel CNS penetrable small molecule targeting Lp-PLA2, being investigated for the treatment of Alzheimer's disease (AD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 08, 2024

                            Lead Product(s) : DPT0416

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ractigen Therapeutics

                            China arrow
                            Aquaexpo
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : University Medical Center Utrecht

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Ractigen Partners with University Medical Center Utrecht to Advance saRNA in Disorders

                            Details : This strategic alliance unites their respective strengths to advance the development of saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 29, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : University Medical Center Utrecht

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hangzhou Highlightll Pharmaceutical

                            China arrow
                            Aquaexpo
                            Not Confirmed

                            Hangzhou Highlightll Pharmaceutical

                            China arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BHV-8000

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Biohaven Pharmaceuticals

                            Deal Size : $970.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Br...

                            Details : Under the agreement, Biohaven and Highlightll will coordinate clinical development across global regions for BHV-8000 (previously TLL-041), an oral, brain-penetrant, dual inhibitor of TYK2 and JAK1 for the treatment of brain disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $10.0 million

                            March 22, 2023

                            Lead Product(s) : BHV-8000

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Biohaven Pharmaceuticals

                            Deal Size : $970.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ractigen Therapeutics

                            China arrow
                            Aquaexpo
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ractigen Therapeutics Receives FDA Orphan Drug Designation For the Novel Oligonucleotide Conjugate RAG-17 for ...

                            Details : RAG-17 is a therapeutic siRNA designed to target and knockdown the expression of SOD1 gene in patients with pathogenic mutations known to cause amyotrophic lateral sclerosi.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            March 03, 2023

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Akeso

                            China arrow
                            Aquaexpo
                            Not Confirmed

                            Akeso

                            China arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AK115

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akeso's NGF Monoclonal Antibody (AK115) Approved To Initiate Clinical Trial In Pain (Including Cancer Pain)

                            Details : AK115 (NGF monoclonal antibody), with the characteristics of long-term safety and non-addictive, will give priority to the evaluation of safety and efficacy in advanced cancer patients, which is expected to bring hope to opioid-resistant advanced cancer ...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 10, 2022

                            Lead Product(s) : AK115

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bened Biomedical

                            China arrow
                            Aquaexpo
                            Not Confirmed

                            Bened Biomedical

                            China arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Plantarum

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Psychobiotic PS128 Consumption Shows Benefits to Parkinson's Symptoms in New Clinical Study

                            Details : Bened Biomedical, a leading Taiwanese probiotic company, has announced a successful clinical study for its PS128 psychobiotic in treating symptoms of Parkinson's disease (PD). The study was led by a neurologist, Dr. Chin-Song Lu, a renowned researcher fo...

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            February 18, 2021

                            Lead Product(s) : Lactobacillus Plantarum

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            WuXi Biologics

                            China arrow
                            Aquaexpo
                            Not Confirmed

                            WuXi Biologics

                            China arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anti-TDP-43 antibody

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : AC Immune

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodi...

                            Details : The partnership focuses on developing AC Immune’s clinical antibody candidate to ensure it has high-affinity for TDP-43 and is capable of preventing the intercellular spread of toxic species.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            November 09, 2020

                            Lead Product(s) : Anti-TDP-43 antibody

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : AC Immune

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth